Long-term use of evolocumab tied to sustained reduction of LDL C and CV events: FOURIER-OLE trial Dr. Kamal Kant Kohli3 Sep 2022 5:30 AM GMTEvolocumab is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor used to lower CVD risk by controlling LDL cholesterol.According to...
Journal Club - Smokers With Heart Disease can add up 5 Years by Quitting Dr. Nandita Mohan4 May 2022 1:06 PM GMTAdverse effects of smoking and heart health in smokers. Smoking cessation appears to be comparable to the use of three targeted drugs in warding off...
Alirocumab addition to statins significantly regresses plaque in non infarct-related coronary arteries MD Bureau22 April 2022 3:30 AM GMTStatins have been shown to reduce cardiovascular adverse events in patients with atherosclerotic disease. In a recent study, researchers have reported...
Oral PCSK9 to drop LDL levels low Dr. Nandita Mohan6 Dec 2021 12:20 PM GMTLow-density lipoprotein (LDL) cholesterol, popularly known as bad cholesterol is major cause of heart disease. LDL C causes build-up of fatty deposits...
Oral PCSK9 inhibitor may significantly reduce LDL C levels: DALLAS, The First Human Trial Dr. Prem Aggarwal3 Dec 2021 8:37 AM GMTLow-density lipoprotein (LDL) cholesterol, popularly known as bad cholesterol is major cause of heart disease. LDL C causes build-up of fatty deposits...
Evolocumab Improves Features Of Plaque Stability In patients of ACS: HUYGENS trial Medical Dialogues Bureau30 Aug 2021 12:45 AM GMTUSA: Repatha (evolocumab) in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved features...
PCSK9 inhibitor Evinacumab may significantly lower LDL cholesterol in FH: NEJM Medha Baranwal21 Aug 2020 6:00 AM GMTDelhi: Evinacumab significantly lowers LDL cholesterol levels in patients with homozygous familial hypercholesterolemia receiving maximum...
PCSK9 inhibitors may improve function of coronary arteries also: JAHA study Dr. Kamal Kant Kohli30 July 2020 3:00 PM GMTResearchers at Johns Hopkins Medicine have found in a pilot study that a six-week course of a cholesterol-lowering medication improved the function of...
PCSK9 inhibitor, statin combo not linked to loss of cognition or mental skills Hina Zahid6 May 2020 12:15 AM GMTThe researchers have examined the cognitive function of the entire FOURIER cohort at two years and found that evolocumab addition to statins...
Alirocumab may cause scleritis with uveal effusion in susceptible patients Dr. Kamal Kant Kohli10 March 2020 7:30 AM GMTAlirocumab has been linked to scleritis with uveal effusion in patient with autoimmune diseases according to a case study. In the literature...
